Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (241-250 of 635) with videos related to

Pageof 64
Sort By:
European Heart Journal|April 14, 2006
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL studyAbhinav Goyal, Kenneth W Mahaffey, Jyotsna Garg, et al.
Circulation. Cardiovascular Interventions|June 18, 2016
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX TrialMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology|February 6, 2016
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX TrialTannas Jatene, Robert A Harrington, Gregg W Stone, et al.
Clinical Cardiology|June 13, 2017
Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effortJessie Kittle, Renato D Lopes, Mingyan Huang, et al.
Contemporary Clinical Trials|January 12, 2011
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trialKenneth W Mahaffey, June L Wampole, Amanda Stebbins, et al.
The American Journal of Cardiology|August 14, 2017
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)Muthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Journal of Thrombosis and Thrombolysis|May 31, 2015
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trialsDominick J Angiolillo, Deepak L Bhatt, Ph Gabriel Steg, et al.
Kidney International Reports|February 12, 2024
Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A <i>Post Hoc</i> Analysis of CREDENCE TrialAkihiko Koshino, Brendon L Neuen, Megumi Oshima, et al.
The Lancet. Diabetes & Endocrinology|October 16, 2020
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trialMegumi Oshima, Brendon L Neuen, Meg J Jardine, et al.
Circulation. Cardiovascular Interventions|October 5, 2019
Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID TrialAman Kansal, Zhen Huang, Frank W Rockhold, et al.
Pageof 64

Showing results (241-250 of 635) with videos related to

Sort By:
Pageof 64
European Heart Journal|April 14, 2006
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL studyAbhinav Goyal, Kenneth W Mahaffey, Jyotsna Garg, et al.
Circulation. Cardiovascular Interventions|June 18, 2016
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX TrialMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology|February 6, 2016
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX TrialTannas Jatene, Robert A Harrington, Gregg W Stone, et al.
Clinical Cardiology|June 13, 2017
Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effortJessie Kittle, Renato D Lopes, Mingyan Huang, et al.
Contemporary Clinical Trials|January 12, 2011
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trialKenneth W Mahaffey, June L Wampole, Amanda Stebbins, et al.
The American Journal of Cardiology|August 14, 2017
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)Muthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Journal of Thrombosis and Thrombolysis|May 31, 2015
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trialsDominick J Angiolillo, Deepak L Bhatt, Ph Gabriel Steg, et al.
Kidney International Reports|February 12, 2024
Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A <i>Post Hoc</i> Analysis of CREDENCE TrialAkihiko Koshino, Brendon L Neuen, Megumi Oshima, et al.
The Lancet. Diabetes & Endocrinology|October 16, 2020
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trialMegumi Oshima, Brendon L Neuen, Meg J Jardine, et al.
Circulation. Cardiovascular Interventions|October 5, 2019
Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID TrialAman Kansal, Zhen Huang, Frank W Rockhold, et al.
Pageof 64